Comparison of PTEN expression in Hashimoto thyroiditis, follicular adenoma, papillary and follicular carcinomas

Aim: Thyroid malignancies account for approximately 3% of all human cancers. A loss or reduction in the expression of a tumor suppressor gene, PTEN has been observed in approximately 40% of thyroid tumors. This change in PTEN expression has been shown to be due to PTEN mutation or deletion. The aim of this study was to compare the PTEN expression among Hashimoto thyroiditis, follicular adenomas and malignant tumors originating from thyroid follicle epithelial cells.Material and Methods: 101 cases of thyroid carcinoma were studied and classified into differentiated types including 15 cases of follicular thyroid carcinomas (FTC), 28 cases of papillary thyroid carcinomas (PTC), 29 cases of follicular adenomas (FA) and 29 cases of Hashimoto thyroiditis (HT). PTEN expression in all the cases were analyzed immunohistochemically.Results: The cytoplasmic and nuclear staining intensity in Hashimoto thyroiditis showed minimal loss of PTEN expression. The nuclear and cytoplasmic staining intensity and percentage in Hashimoto thyroiditis and follicular adenomas were similar. In most of the papillary carcinoma samples, PTEN expression was lost as deduced from cytoplasmic and nuclear staining intensity. While the loss of nuclear PTEN expression was the highest in follicular carcinoma, the cytoplasmic loss was minimal.Conclusions: Loss of PTEN expression is more pronounced in papillary and follicular carcinomas than benign lesions. PTEN has been shown to play an oncogenic role in papillary and follicular carcinoma. PTEN expression loss can be used as a new biomarker in PTC and FTC cases.

PDF

___

1. Kong Y, Yin J, Fu Y, et al. Suppression of Elk1 inhibits thyroid cancer progression by mediating PTEN expression. Oncology Reports 2018;40:1769-76.
2. Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto’s thyroiditis and thyroid cancer in 64,628 Patients. Front Oncol 2017;7:53.
3. Lee JC, Sidhu SB. Papillary thyroid cancer: the most common endocrine malignancy. Endocrinology Today 2013;2:15-20.
4. Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s Thyreoiditis: Clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res 2019;21.
5. Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 2013;168:343-9.
6. Kurukahvecioglu O, Taneri F, Yüksel O, et al. Total thyreoidectomy for the treatment of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther 2007;24:510-6.
7. Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol 2002;10:141-6.
8. Huang BY, Hseuh C, Chao TC, et al. Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 2011;22:144-9.
9. Pisanu A, Piu S, Cois A, et al. Coexisting Hashimoto’s thyroiditis with differentiated thyroid cancer and benign thyroid diseases: indications for thyroidectomy. Chir Ital 2003;55:365-72.
10. Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001;25:632-7.
11. Consorti F, Loponte M, Milazzo F, et al. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 2010;45:333-7.
12. Razavi MH, Modarressi P, Yaghmaei SM, et al. Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? Endocrine 2017;57:428-35.
13. Beg S, Siraj AK, Jehan Z, et al. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. British J Cancer 2015;112:1938-43.
14. Xu J, Cai J, Jin X, et al. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway. Oncology Reports 2015;34:1424-30.
15. Larson SD, NJ Lindsey, Taylor SR. Increased incıdence of well-differentiated thyroid cancer associated with Hashimoto’s Thyroiditis and the role of the PI3K/Akt pathway. J Am Coll Surg 2007;204:764-75.
16. Şamdancı E, Şahin N, Aydın NE. Histopathologic subtypes of surgically resected papillary thyroid carcinomas in Malatya region. HYPERLINK “http://www.totmdergisi.org/archive.php” t “_top”Journal of Inonu University Medical Faculty 2010;17:77-80.
17. Lin JD, Hsuen C, Chen JY, et al. Cystic change in thyroid cancer. Anz J Surg 2007;77:450-4.
18. Podnos YD, Smith DD, Wagman LD, et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 2007;96:3-7.
19. Fujimoto Y, Obara T, Yamashita T. Papillary thyroid carcinoma: Rationale for hemithyroidectomy and regional node dissection. In:Clark OH, Duh OY. Textbook of endocrine Surgery. 1st edition 2003;82-93.
20. Corapcioglu D, Sak SD, Delibasi T, et al. Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas. J Transl Med 2006;4:28.
21. Rosai J. Rosai and Ackerman′s. Surgical Pathology. 9th edition. Mosby, China 2004;515-68.
22. DeLellis RA, et al. Pathology and genetics of tumours of endocrine organs. WHO Classification of Tumours, 3rd Edition 8 IARC 2004;49-133.
23. Lionel ML, Suzanne JB. PTEN function in normal and neoplastic growth. Cancer Letters 2006;241:184-96.
24. Oliver G, Aurel P, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. American Journal of Pathology 2000;156:1693-700.
25. Carla DL, Gianluca T, et al. PTEN and Egr-1 expresion in thyroid proliferative lesions. Cancer Letters 2005;224:105-9.
26. Bruni P, Boccia A, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000;19:3146-55.
27. Frisk T, Foukakis T, Dwight T, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosome Cancer 2002;35:74-80.
28. Weng LP, Gimm O, et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Human Mol Genet 2001;10:251-8.